Janus激酶-信号转导及转录激活因子信号通路抑制剂在白癜风治疗中的新进展

doi:10.35541/cjd.20230173

中华皮肤科杂志 ›› 2024, Vol. 57 ›› Issue (1): 71-75.doi: 10.35541/cjd.20230173

Janus激酶-信号转导及转录激活因子信号通路抑制剂在白癜风治疗中的新进展

古丽孜巴·图尔荪¹,屈园园²

¹新疆医科大学研究生院，乌鲁木齐 830001；²新疆维吾尔自治区人民医院皮肤性病科新疆皮肤病临床医学研究中心新疆皮肤病研究重点实验室（XJYS1707），乌鲁木齐 830001

收稿日期:2023-03-29 修回日期:2023-11-28 发布日期:2024-01-05
通讯作者: 屈园园 E-mail:quyy711@163.com
基金资助:
中国研究型医院学会科研课题（Y2021FH-PFK06）

New advances in the treatment of vitiligo with JAK-STAT inhibitors

Guliziba·Tuersun¹, Qu Yuanyuan²

¹Graduate School of Xinjiang Medical University, Urumqi 830001, China; ²Department of Dermatology and Venereology, People′s Hospital of Xinjiang Uygur Autonomous Region, Xinjiang Clinical Research Center for Dermatologic Diseases, Xinjiang Key Laboratory of Dermatology Research（XJYS1707）, Urumqi 830001, China

Received:2023-03-29 Revised:2023-11-28 Published:2024-01-05
Contact: Qu Yuanyuan E-mail:quyy711@163.com
Supported by:
Scientific Research Project of Chinese Research Hospital Association（Y2021FH-PFK06）

摘要/Abstract

摘要： 【摘要】近年来，随着对白癜风发病机制的深入研究，Janus激酶（JAK）-信号转导及转录激活因子（STAT）信号通路越来越受到关注。本文综述了JAK-STAT信号通路在白癜风发生过程中的作用，并回顾了目前正在研究或已用于治疗白癜风的JAK-STAT抑制剂。

关键词: 白癜风, Janus激酶类, STAT转录因子类, JAK-STAT抑制剂, 治疗

Abstract: 【Abstract】 In recent years, with the in-depth research on the pathogenesis of vitiligo, the Janus kinase （JAK）-signal transducer and activator of transcription （STAT） pathway has attracted more and more attention. This review summarizes the role of the JAK-STAT signaling pathway in the development of vitiligo, as well as JAK-STAT inhibitors that are currently being studied or have been used in the treatment of vitiligo.

Key words: Vitiligo, Janus kinases, STAT transcription factors, JAK-STAT inhibitor, Treatment

古丽孜巴·图尔荪屈园园. Janus激酶-信号转导及转录激活因子信号通路抑制剂在白癜风治疗中的新进展[J]. 中华皮肤科杂志, 2024,57(1):71-75. doi:10.35541/cjd.20230173

Guliziba·Tuersun, Qu Yuanyuan. New advances in the treatment of vitiligo with JAK-STAT inhibitors[J]. Chinese Journal of Dermatology, 2024, 57(1): 71-75.doi:10.35541/cjd.20230173

参考文献 40

［1］	Ciechanowicz P, Rakowska A, Sikora M, et al. JAK⁃inhibitors in dermatology: current evidence and future applications［J］. J Dermatolog Treat, 2019,30（7）:648⁃658. doi: 10.1080/09546634. 2018.1546043.
［2］	Rosmarin D, Passeron T, Pandya AG, et al. Two phase 3, randomized, controlled trials of ruxolitinib cream for vitiligo［J］. N Engl J Med, 2022,387（16）:1445⁃1455. doi: 10.1056/NEJMoa 2118828.
［3］	Zhang J, Qi F, Dong J, et al. Application of baricitinib in dermatology［J］. J Inflamm Res, 2022,15:1935⁃1941. doi: 10. 2147/JIR.S356316.
［4］	Komnitski M, Komnitski A, Komnitski Junior A, et al. Partial repigmentation of vitiligo with tofacitinib, without exposure to ultraviolet radiation［J］. An Bras Dermatol, 2020,95（4）:473⁃476. doi: 10.1016/j.abd.2019.08.032.
［5］	Olamiju B, Craiglow BG. Tofacitinib cream plus narrowband ultraviolet B phototherapy for segmental vitiligo in a child［J］. Pediatr Dermatol, 2020,37（4）:754⁃755. doi: 10.1111/pde.14159.
［6］	Qi F, Liu F, Gao L. Janus kinase inhibitors in the treatment of vitiligo: a review［J］. Front Immunol, 2021,12:790125. doi: 10. 3389/fimmu.2021.790125.
［7］	Favoino E, Prete M, Catacchio G, et al. Working and safety profiles of JAK/STAT signaling inhibitors. Are these small molecules also smart?［J］. Autoimmun Rev, 2021,20（3）:102750. doi: 10.1016/j.autrev.2021.102750.
［8］	Niu C, Xie H, Aisa HA. Janus kinase inhibitors: a review of their application in the vitiligo［J］. Mini Rev Med Chem, 2021,21（20）:3203⁃3218. doi: 10.2174/1389557521666210325120233.
［9］	Sheikh A, Rafique W, Owais R, et al. FDA approves ruxolitinib （opzelura） for vitiligo therapy: a breakthrough in the field of dermatology［J］. Ann Med Surg （Lond）, 2022,81:104499. doi: 10.1016/j.amsu.2022.104499.
［10］	Pandya AG, Harris JE, Lebwohl M, et al. Addition of narrow⁃band UVB phototherapy to ruxolitinib cream in patients with vitiligo［J］. J Invest Dermatol, 2022,142（12）:3352⁃3355. doi: 10.1016/j.jid.2022.05.1093.
［11］	Craiglow BG, King BA. Tofacitinib citrate for the treatment of vitiligo: a pathogenesis⁃directed therapy［J］. JAMA Dermatol, 2015,151（10）:1110⁃1112. doi: 10.1001/jamadermatol.2015.1520.
［12］	Moore AY, Maberry S. 26966 Tofacitinib treats unresponsive vitiligo and elevated thyroid peroxidase antibodies［J］. J Am Acad Dermatol, 2021,85（3 suppl）:AB124. doi:10.1016/j.jaad. 2021.06.515.
［13］	Scheinberg M, Ferreira SB, Santos D. Tofacitinib⁃induced remission simultaneously in arthritis and vitiligo［J］. Eur J Rheumatol, 2021,8（1）:55⁃56. doi: 10.5152/eurjrheum.2020. 20007.
［14］	Liu LY, Strassner JP, Refat MA, et al. Repigmentation in vitiligo using the Janus kinase inhibitor tofacitinib may require concomitant light exposure［J］. J Am Acad Dermatol, 2017,77（4）:675⁃682.e1. doi: 10.1016/j.jaad.2017.05.043.
［15］	Liang J, Yu Y, Li C, et al. Tofacitinib combined with melanocyte protector α⁃MSH to treat vitiligo through dextran based hydrogel microneedles［J］. Carbohydr Polym, 2023,305:120549. doi: 10.1016/j.carbpol.2023.120549.
［16］	Yagi K, Ishida Y, Otsuka A, et al. Two cases of vitiligo vulgaris treated with topical Janus kinase inhibitor delgocitinib［J］. Australas J Dermatol, 2021,62（3）:433⁃434. doi: 10.1111/ajd. 13572.
［17］	Jin R, Zhou M, Lin F, et al. Pathogenic Th2 cytokine profile skewing by IFN⁃γ⁃responding vitiligo fibroblasts via CCL2/CCL8［J］. Cells, 2023,12（2）:217. doi: 10.3390/cells12020217.
［18］	Dong J, Huang X, Ma LP, et al. Baricitinib is effective in treating progressing vitiligo in vivo and in vitro［J］. Dose Response, 2022,20（2）:15593258 221105370. doi: 10.1177/15593258221105370.
［19］	Mumford BP, Gibson A, Chong AH. Repigmentation of vitiligo with oral baricitinib［J］. Australas J Dermatol, 2020,61（4）:374⁃376. doi: 10.1111/ajd.13348.
［20］	李子航, 王睿, 张昕. 巴瑞替尼治疗进展期白癜风疗效分析［J］. 中国麻风皮肤病杂志, 2023,39（2）:102⁃105. doi: 10.12144/ zgmfskin202302102.
［21］	Aclaris Therapeutics, Inc. A study of ATI⁃50002 topical solution for the treatment of vitiligo［EB/OL］. （2020⁃11⁃30）［2023⁃11⁃28］. https://clinicaltrials.gov/ct2/show/NCT03468855.
［22］	Su X, Luo R, Ruan S, et al. Efficacy and tolerability of oral upadacitinib monotherapy in patients with recalcitrant vitiligo［J］. J Am Acad Dermatol, 2023,89（6）:1257⁃1259. doi: 10.1016/j.jaad.2023.07.1016.
［23］	Pan T, Mu Y, Shi X, et al. Concurrent vitiligo and atopic dermatitis successfully treated with upadacitinib: a case report［J］. J Dermatolog Treat, 2023,34（1）:2200873. doi: 10.1080/09546634.2023.2200873.
［24］	Ezzedine K, Peeva E, Yamaguchi Y, et al. Efficacy and safety of oral ritlecitinib for the treatment of active nonsegmental vitiligo: a randomized phase 2b clinical trial［J］. J Am Acad Dermatol, 2023,88（2）:395⁃403. doi: 10.1016/j.jaad.2022.11.005.
［25］	Guttman⁃Yassky E, Del Duca E, Da Rosa JC, et al. Improvements in immune/melanocyte biomarkers with JAK3/TEC family kinase inhibitor ritlecitinib in vitiligo［J］. J Allergy Clin Immunol, 2023:S0091⁃6749（23）01202⁃01202. doi: 10.1016/j.jaci.2023. 09.021.
［26］	Huang X, Ding X. Jak inhibitors in vitiligo: a meta analysis［J/OL］. Chin Med J （Engl）, 2023,136（23）:2897⁃2898. doi: 10.1097/CM9. 0000000000002581.
［27］	Phan K, Phan S, Shumack S, et al. Repigmentation in vitiligo using janus kinase （JAK） inhibitors with phototherapy: systematic review and meta⁃analysis［J］. J Dermatolog Treat, 2022,33（1）:173⁃177. doi: 10.1080/09546634.2020.1735615.
［28］	Narla S, Oska S, Lyons AB, et al. Association of myalgias with compounded topical Janus kinase inhibitor use in vitiligo［J］. JAAD Case Rep, 2020,6（7）:637⁃639. doi: 10.1016/j.jdcr.2020. 05.002.
［29］	Ytterberg SR, Bhatt DL, Connell CA. Cardiovascular and cancer risk with tofacitinib in rheumatoid arthritis. reply［J］. N Engl J Med, 2022,386（18）:1768. doi: 10.1056/NEJMc2202778.
［30］	Sardana K, Muddebihal A, Khurana A. JAK inhibitors in vitiligo: what they hit and what they miss⁃an immunopathogenesis based exposition of existing evidence［J］. Expert Rev Clin Pharmacol, 2023:1⁃7. doi: 10.1080/17512433.2023.2285011.
［31］	Noël M, Gagné C, Bergeron J, et al. Positive pleiotropic effects of HMG⁃CoA reductase inhibitor on vitiligo［J］. Lipids Health Dis, 2004,3:7. doi: 10.1186/1476⁃511X⁃3⁃7.
［32］	Shaker E, Allam SH, Mabrouk MM, et al. Simvastatin and non⁃segmental vitiligo: a new potential treatment option?［J］. Dermatol Ther, 2022,35（12）:e15969. doi: 10.1111/dth.15969.
［33］	Zhang S, Zdravković TP, Wang T, et al. Efficacy and safety of oral simvastatin in the treatment of patients with vitiligo［J］. J Investig Med, 2021,69（2）:393⁃396. doi: 10.1136/jim⁃2020⁃001390.
［34］	Verma D, Hussain K, Namiq KS, et al. Vitiligo: the association with metabolic syndrome and the role of simvastatin as an immunomodulator［J］. Cureus, 2021,13（3）:e14029. doi: 10.7759/ cureus.14029.
［35］	Agarwal P, Rashighi M, Essien KI, et al. Simvastatin prevents and reverses depigmentation in a mouse model of vitiligo［J］. J Invest Dermatol, 2015,135（4）:1080⁃1088. doi: 10.1038/jid.2014. 529.
［36］	Vanderweil SG, Amano S, Ko WC, et al. A double⁃blind, placebo⁃controlled, phase⁃Ⅱ clinical trial to evaluate oral simvastatin as a treatment for vitiligo［J］. J Am Acad Dermatol, 2017,76（1）:150⁃151.e3. doi: 10.1016/j.jaad.2016.06.015.
［37］	Chang Y, Li S, Guo W, et al. Simvastatin protects human melanocytes from H2O2⁃induced oxidative stress by activating Nrf2［J］. J Invest Dermatol, 2017,137（6）:1286⁃1296. doi: 10. 1016/j.jid.2017.01.020.
［38］	Jian Z, Tang L, Yi X, et al. Aspirin induces Nrf2⁃mediated transcriptional activation of haem oxygenase⁃1 in protection of human melanocytes from H2O2⁃induced oxidative stress［J］. J Cell Mol Med, 2016,20（7）:1307⁃1318. doi: 10.1111/jcmm.12812.
［39］	Rodrigues JL, Rodrigues LR. Biosynthesis and heterologous production of furanocoumarins: perspectives and current challenges［J］. Nat Prod Rep, 2021,38（5）:869⁃879. doi: 10. 1039/d0np00074d.
［40］	Niu C, Zang D, Aisa HA. Study of novel furocoumarin derivatives on anti⁃vitiligo activity, molecular docking and mechanism of action［J］. Int J Mol Sci, 2022,23（14）:7959. doi: 10.3390/ijms23147959.

[1]	戴叶芹宋秀祖. 毛囊及毛囊细胞移植在白癜风治疗中的应用进展[J]. 中华皮肤科杂志, 2024, 0(3): 20230274-e0230274.
[2]	中国医师协会皮肤科医师分会中华医学会皮肤性病学分会中国医疗保健国际交流促进会皮肤医学分会疑难重症及罕见病国家重点实验室国家皮肤与免疫疾病临床医学研究中心. 特应性皮炎治疗药物应用管理专家共识（2024版）[J]. 中华皮肤科杂志, 2024, 57(2): 97-108.
[3]	中国“一带一路”皮肤病专病联盟分枝杆菌病研究联盟中国麻风防治协会皮肤性病检验与诊断分会. 中国皮肤非结核分枝杆菌病诊治专家共识（2024版）[J]. 中华皮肤科杂志, 2024, 57(2): 109-118.
[4]	孙玮蔚陈健儒李舒丽高天文李春英. 白癜风小鼠模型抑郁样行为的观察[J]. 中华皮肤科杂志, 2024, 57(2): 147-154.
[5]	王涛武毅靳虹戴叶芹彭建中许爱娥宋秀祖. 回顾性分析电解白发联合毛囊移植治疗25例毛发部位白癜风的疗效[J]. 中华皮肤科杂志, 2024, 57(1): 46-49.
[6]	中国中西医结合学会皮肤性病专业委员会皮肤肿瘤学组中国抗癌协会黑色素瘤专业委员会. [开放获取] 人干扰素α1b治疗黑色素瘤专家共识（2024版）[J]. 中华皮肤科杂志, 2024, 57(1): 1-7.
[7]	陈慧李冰李春英郭伟楠. 水刀磨削或电动磨削联合负压吸疱自体表皮移植术治疗白癜风的疗效比较[J]. 中华皮肤科杂志, 2024, 57(1): 43-45.
[8]	贺楷乔李舒丽李柏樟刘玲李春英. 白癜风光疗复色模式的临床观察及其影响因素分析[J]. 中华皮肤科杂志, 2024, 57(1): 23-28.
[9]	马晶晶亢盼郭森坚哲李春英李舒丽. 转录因子TFAP2B在健康人及白癜风患者表皮黑色素细胞中的表达模式[J]. 中华皮肤科杂志, 2024, 57(1): 29-33.
[10]	张倩张金娥郭森宋璞高琳李春英. CO2点阵激光联合氟尿嘧啶/复方倍他米松注射液导入治疗白癜风的临床观察[J]. 中华皮肤科杂志, 2024, 57(1): 34-38.
[11]	宣依洁杨奕雯王琛徐中奕项蕾红张成锋. 进展期非节段型白癜风患者对系统糖皮质激素治疗反应的相关影响因素研究[J]. 中华皮肤科杂志, 2024, 57(1): 17-22.
[12]	李舒丽李春英. [开放获取] 白癜风靶向药物临床应用进展及前景[J]. 中华皮肤科杂志, 2024, 57(1): 12-16.
[13]	李春英陈健儒李舒丽. 白癜风代谢重塑：进展和未来[J]. 中华皮肤科杂志, 2024, 57(1): 8-11.
[14]	高艳王鹏康晓静. 卡波西肉瘤治疗研究新进展[J]. 中华皮肤科杂志, 2024, 57(1): 85-89.
[15]	曾蕊徐秀莲. [开放获取] 窄谱中波紫外线联合其他方法治疗白癜风的研究进展[J]. 中华皮肤科杂志, 2024, 57(1): 75-78.

Janus激酶-信号转导及转录激活因子信号通路抑制剂在白癜风治疗中的新进展

New advances in the treatment of vitiligo with JAK-STAT inhibitors

PDF

可视化

摘要/Abstract

引用本文

使用本文

参考文献 40

相关文章 15

Metrics

本文评价

推荐阅读 10